A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants

NCT02530060 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC

Sponsor

Janssen Pharmaceutical K.K.